Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks

• Michael Migden, MD,
• Carmen Loquai, MD, PhD,
• Caroline Robert, MD, PhD,
• Jean-François Baurain, MD, PhD,
• Nicholas Squittieri, MD,
• Ramon Arntz, Dr,
• Jörg Dierlamm, BSc,
• Brigitte Dréno, MD, PhD

Affiliations

Michael Migden, MD

Department of Dermatology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Head and Neck Surgery, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas; Correspondence to: Michael Migden, MD, 6655 Travis St, #700, Houston, TX 77030

Carmen Loquai, MD, PhD

Department of Dermatology, University Medical Center Mainz, Mainz, Germany

Caroline Robert, MD, PhD

Department of Dermatology, Institut Gustave Roussy and Paris-Saclay University, Villejuif, France

Jean-François Baurain, MD, PhD

Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Institute for Experimental and Clinical Research, Université catholique de Louvain, Brussels, Belgium

Nicholas Squittieri, MD

Medical Affairs Oncology, Sun Pharmaceutical Industries, Inc, Princeton, New Jersey

Ramon Arntz, Dr

Sun Pharmaceutical Industries, (Europe) B.V., Hoofddorp, North Holland, the Netherlands

Jörg Dierlamm, BSc

Sun Pharmaceutical Industries, (Europe) B.V., Hoofddorp, North Holland, the Netherlands

Brigitte Dréno, MD, PhD

Department of Dermatology, University Hospital Nantes, Nantes, France